StemCell Therapy

A rating of 89 puts Regeneron Pharmaceuticals Inc (REGN) near the top of the Biotechnology industry according to InvestorsObserver. Regeneron Pharmaceuticals Inc's score of 89 means it scores higher than 89% of stocks in the industry. Regeneron Pharmaceuticals Inc also received an overall rating of 77, putting it above 77% of all stocks. Biotechnology is ranked 13 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 77 means the stock is more attractive than 77 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Regeneron Pharmaceuticals Inc (REGN) stock has fallen -3.2% while the S&P 500 has risen 0.39% as of 2:13 PM on Friday, Jul 10. REGN is down -$20.48 from the previous closing price of $640.63 on volume of 504,426 shares. Over the past year the S&P 500 is higher by 5.48% while REGN has risen 112.51%. REGN earned $19.90 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 31.1.

To screen for more stocks like REGN click here.

Read more:
Is Regeneron Pharmaceuticals Inc (REGN) a Winner in the Biotechnology Industry? - InvestorsObserver

This entry was posted on July 10, 2020 at 8:44 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |